Sanofi and AstraZeneca's RSV antibody cuts hospitalizations by 83% in late-stage study, as $10B market battle heats up

Andrew Dunn

Senior Biopharma Correspondent

Sanofi and AstraZeneca’s RSV antibody nirsevimab cut the rate of hospitalizations by 83% in a Phase IIIb trial, the French pharma giant said Friday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi and AstraZeneca's RSV antibody cuts hospitalizations by 83% in late-stage study, as $10B market battle heats up

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Sanofi and As­traZeneca's RSV an­ti­body cuts hos­pi­tal­iza­tions by 83% in late-stage study, as $10B mar­ket bat­tle heats up

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Sanofi and AstraZeneca's RSV antibody cuts hospitalizations by 83% in late-stage study, as $10B market battle heats up

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra